The MIMESIS team is proud to be part of POCUSI (Point of Care UltraSound for Screening & Intervention), a new strategic consortium developing a next generation of intelligent, software-based, frugal ultrasound devices.
Selected as part of the France 2030 plan under the national “Innovation in Medical Imaging” call for projects, POCUSI brings together four French partners with the ambition of building a sovereign French digital ultrasound industry.
A disruptive approach to point-of-care ultrasound
POCUSI proposes a disruptive approach to point-of-care ultrasound, making it accessible to non-expert operators at the patient’s location. The project leverages the computing power of standard computers and tablets to deliver operator assistance and quantitative measurements directly related to the severity of chronic diseases.
Clinical focus: chronic liver diseases
POCUSI primarily targets chronic liver diseases and their complications (hepatocellular cancers, cirrhosis), as well as the monitoring of metabolic and cardiovascular risk factors. Patients with obesity, type 2 diabetes, or metabolic dysfunction-associated steatotic liver disease (MASLD) represent at least 30% of the global population and would benefit greatly from simple, accessible monitoring tools.
The project aims to democratize ultrasound throughout the care pathway, from screening to interventional guidance of therapeutic procedures.
The consortium
The POCUSI consortium, representing a total investment of €6.7 million over five years (€4.7M funded by the French government through Bpifrance), brings together:
- E-Scopics — next-generation software platform and its first commercial product, Hépatoscope
- Vermon — high-performance ultrasound probes
- IHU Strasbourg — clinical and preclinical trial expertise
- MIMESIS (CNRS, Inria, Université de Strasbourg) — data-driven medical simulation tools
This project is funded as part of the France 2030 plan.
